Aldevron will begin construction in August of 2019 on a 14-acre biologics campus in Fargo, N.D., where it is currently headquartered. The first phase comprises a two-story, 189,000-sf facility for the manufacture of plasmid DNA, proteins, mRNA, and antibodies. Increasing Aldevron’s GMP and GMP-Source™ production capacity up to tenfold, the structure will connect to the company's existing GMP facility and is expected to be fully operational by early 2021. In total, three new buildings will be built over the next three to five years, an expansion which will also enable large-scale production of novel products like nanoplasmids and minicircles. The completed 500,000-sf campus will include a 20,000-sf quality control and product storage building, an 89,000-sf administration and customer service center, and a 96,000-sf structure accommodating research, development, training, and technical operations.
